MKN45、MKN-45、MKN45细胞、MKN-45细胞、

MKN45、MKN-45、MKN45细胞、MKN-45细胞、MKN45人胃癌细胞

Cell line name MKN45

Synonyms MKN-45; MKN 45

Accession CVCL_0434

Resource Identification Initiative To cite this cell line use: MKN45 (RRID:CVCL_0434)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: JFCR39 cancer cell line panel.

Part of: JFCR45 cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

Population: Japanese.

Characteristics: MET-amplified, contains 12-13 copies of the gene (PubMed=29435981).

Doubling time: 30-33 hours (PubMed=3962675); 33 hours (PubMed=29435981); 30-38 hours (CelloPub=CLPUB00584); 16 hours (PubMed=2105279); ~60 hours (DSMZ=ACC-409).

Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Caution: Was indicated not to have a TP53 mutation in PubMed=1370612 and PubMed=15900046.

Misspelling: MKN46; Cosmic=968349.

Misspelling: MNK-45; Note=Occasionally.

Misspelling: MNK45; Note=Occasionally.

Misspelling: NKM-45; Note=Occasionally.

Misspelling: NKM45; Note=Occasionally.

Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.

PubMed=9023415; DOI=10.1006/cimm.1996.1062

Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.

HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.

Cell. Immunol. 175:101-110(1997)

 

PubMed=9247707; DOI=10.1080/15216549700202901

Hatakeyama S., Gao Y.-H., Ohara-Nemoto Y., Kataoka H., Satoh M.

Expression of bone morphogenetic proteins of human neoplastic epithelial cells.

Biochem. Mol. Biol. Int. 42:497-505(1997)

 

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D

Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Screening the p53 status of human cell lines using a yeast functional assay.

Mol. Carcinog. 19:243-253(1997)

 

PubMed=9665481; DOI=10.1016/S0002-9440(10)65561-7; PMCID=PMC1852940

Paciucci R., Vila M.R., Adell T., Diaz V.M., Tora M., Nakamura T., Real F.X.

Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.

Am. J. Pathol. 153:201-212(1998)

 

PubMed=11107048; DOI=10.1046/j.1440-1827.2000.01117.x

Yokozaki H.

Molecular characteristics of eight gastric cancer cell lines established in Japan.

Pathol. Int. 50:767-777(2000)

 

PubMed=11314020; DOI=10.1038/sj.onc.1204160

Kataoka H., Miura Y., Joh T., Seno K., Tada T., Tamaoki T., Nakabayashi H., Kawaguchi M., Asai K., Kato T., Itoh M.

Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1.

Oncogene 20:869-873(2001)

 

PubMed=11668190; DOI=10.1177/002215540104901105

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

Immunocytochemical analysis of cell lines derived from solid tumors.

J. Histochem. Cytochem. 49:1369-1378(2001)

 

PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x; PMCID=PMC11160020

Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H., Okanoue T., Inazawa J.

Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization.

Cancer Sci. 96:100-110(2005)

 

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234

Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.

Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.

Mol. Cancer Ther. 4:399-412(2005)

 

PubMed=15900046; DOI=10.1093/jnci/dji133

Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.

p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.

J. Natl. Cancer Inst. 97:765-777(2005)

 

PubMed=15901131; DOI=10.1016/j.prp.2005.01.002

Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.

Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines.

Pathol. Res. Pract. 201:109-115(2005)

 

PubMed=18804159; DOI=10.1016/j.ygeno.2008.08.002

Jung J.-J., Jeung H.-C., Chung H.C., Lee J.O., Kim T.S., Kim Y.T., Noh S.H., Rha S.Y.

In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer.

Genomics 93:52-61(2009)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)